To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

Mucolipidosis type IV

From Wikipedia, the free encyclopedia

Mucolipidosis type IV
SpecialtyEndocrinology Edit this on Wikidata

Mucolipidosis type IV (ML IV, ganglioside sialidase deficiency, or ML4) is an autosomal recessive lysosomal storage disorder. Individuals with the disorder have many symptoms including delayed psychomotor development and various ocular aberrations. The disorder is caused by mutations in the MCOLN1 gene, which encodes a non-selective cation channel, mucolipin1.[1][2] These mutations disrupt cellular functions and lead to a neurodevelopmental disorder through an unknown mechanism. Researchers dispute the physiological role of the protein product and which ion it transports.[3]

YouTube Encyclopedic

  • 1/5
    Views:
    1 769
    1 824
    318
    1 316
    588
  • Trash-Talking with Lysosomes - Rosa Puertollano, NIH IRP Scientist
  • Rational therapeutics for genetic conditions - Hal Dietz
  • "Lysosomes and Age-related Macular Degeneration" - Claire Mitchell, PhD
  • Ion channel
  • Lois Weisman on Yeast to Study Neurological Diseases at Conte Center’s DNA Day

Transcription

>> I think that this stage, when I do the one experiment, maybe it's been basically risky but you know if it's going to work, that you hope is going to work. And you would go to the microscope and you look at these and it worked, just as you predicted, and you feel how your heart start beating because you know this is something good. And that only happened to me maybe two or three times so far in my life. My laboratory is interested in understanding how cells work. And, in particular, we're very interested in lysosomes. This is an organelle inside of the cells. I need to basically then [inaudible] organelle. It's not to me really important to be great differing materials. It could be carbon, nutrients, pathogens. So in my laboratory we basically have two proteates [phonetic spelling]. We want to understand how lysosomes work in normal conditions; and we want to understand how they work under pathological conditions, why, when lysosomes don't work properly, sometimes that led to human disease. In humans, there are like 70 different diseases that are caused by mutations in lysosomal proteins. And, specifically, we work with mucolipidosis type IV. It's caused by mutations in mucolipin-1 that is a cation channel that localize to the lysosome. And we are trying to understand what is the function of this protein and why, when this protein is mutated, lysosomes don't work properly; and that led to neural degeneration, blindness, and many different problems. The initial step is going to be try to learn a little more about the physiological function of those proteins in vivo. So we are moving a little more toward where animal models, and we are now doing different experiments, as I say, in mouse but also in zebrafish. So, for example, in zebrafish, we just generated an [inaudible] for mucolipin-1. And I think this is going to be very useful because zebrafish have the advantage that you can follow their embryonic development because those animal are transparent and it's very easy to monitor, for example, the formation of the eye, the brain, the different embryo [inaudible] cells just by looking at the animal. >> Usually I start exploring the localization of proteins basically in the cells using microscopic technologies, techniques. But then we use other approaches like biochemistry to try to understand the interaction between proteins. >> So right now I'm doing a TUNEL staining for my zebrafish. Basically, I have a nome [phonetic spelling] called lime, a genome called lime [phonetic spelling], and I want to characterize their phenotype. So I'm watching those fish and, later on, I will stain the fish with fluorescence. So TUNEL staining is specific for apoptosis detection. >> You know, I think the thing that was really cool when I first joined here is I learned a lot very quickly. You know, a lot of things are very accessible, which allows you to answer questions a lot more quickly. So, instead of having to wait for reagents to come in or maybe you don't have an instrument you need, it's all there; so you can really start addressing things very quickly. And that surprised me, really, just how quickly I was able to do things and to learn a lot in a short amount of time. >> But what we are learning, and I think it's important to keep that in mind, it can then be applicable to many different diseases by understanding how mucolipin-1 is regulating fusion of lysosomes with other [inaudible]. We found that [inaudible] is really important in lysosome [inaudible] disorders, and now we are finding that many different diseases have very common characteristics to that. When you really know you have a beautiful story and it's something that makes sense but is unexpected and no one interfered, and then this energy that you get, one can do no more about what you found, I think this rising adrenaline that you get when you get a really good result, I think that that make the days, like, very good days.

Signs and symptoms

Most patients with ML IV show psychomotor retardation (i.e., delayed development of movement and coordination), corneal opacity, retinal degeneration and other ophthalmological abnormalities. Other symptoms include agenesis of the corpus callosum, iron deficiency resulting from an absence of acid secretion in the stomach, achlorhydria. Achlorhydria in these patients results in an increase in blood gastrin levels. These symptoms typically manifest early in life (within the first year). After disease onset there occurs a period of stability, typically lasting two to three decades during which very little disease progression occurs.[4]

Pathophysiology

Mucolipidosis type IV has an autosomal recessive pattern of inheritance.

Mucolipin1 is thought to be localized in endosomes. An important property of mucolipin1 is that decreasing pH (acidification) results in deactivation of the protein, likely through an assembly defect. There are at least 29 known mutations in MCOLN1, located throughout the gene.[5] Many of the known mutations result in no expression of mucolipin1. Milder mutations, such as ΔF408 and V446L, produce a dysfunctioning form of the cation channel.[6] Mutations that alter only the C-terminal of the protein also result in a mild phenotype of the disorder, usually sparing the brain.[7] ML IV causes affected cells to accumulate auto-fluorescent vacuoles considered to be aberrant lysosomes.[8] Several evidences exist for a defect in both exocytosis and endocytosis.[9] There are conflicting indications of abnormal lysosomal pH in MLIV.[citation needed] It is not yet clear why these abnormalities will cause incomplete development of the brain, achlorhydria, and failure in the maintenance of retinal tissue.

Diagnosis

Diagnosis includes genetic testing and Gastrin blood test to check for low iron in the blood.

Treatment

There is no specific treatment to this disorder. However, several symptoms may be alleviated. For instance, anemia is treated by iron supplements. Some of the movement deficiencies may be corrected with orthopedic intervention. The corneal clouding can be, at least, temporarily corrected by corneal transplantation. See the equivalent section in the main mucolipidosis article.

Epidemiology

Mucolipidosis type IV is severely under-diagnosed. It is often misdiagnosed as cerebral palsy. In the Ashkenazi Jewish population there are two severe mutations with a higher carrier frequency[10] of 1:90 to 1:100.[11]

References

  1. ^ Nilius, B.; Owsianik, G.; Voets, T.; Peters, J. A. (2007). "Transient Receptor Potential Cation Channels in Disease". Physiological Reviews. 87 (1): 165–217. doi:10.1152/physrev.00021.2006. PMID 17237345.
  2. ^ Sun, M.; Goldin, E; Stahl, S; Falardeau, J. L.; Kennedy, J. C.; Acierno Jr, J. S.; Bove, C; Kaneski, C. R.; Nagle, J; Bromley, M. C.; Colman, M; Schiffmann, R; Slaugenhaupt, S. A. (2000). "Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel". Human Molecular Genetics. 9 (17): 2471–8. doi:10.1093/hmg/9.17.2471. PMID 11030752.
  3. ^ Dong, Xian-Ping; Cheng, Xiping; Mills, Eric; Delling, Markus; Wang, Fudi; Kurz, Tino; Xu, Haoxing (2008). "The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel". Nature. 455 (7215): 992–6. Bibcode:2008Natur.455..992D. doi:10.1038/nature07311. PMC 4301259. PMID 18794901.
  4. ^ Wakabayashi, K.; Gustafson, A. M.; Sidransky, E.; Goldin, E. (2011). "Mucolipidosis type IV: An update". Molecular Genetics and Metabolism. 104 (3): 206–213. doi:10.1016/j.ymgme.2011.06.006. PMC 3205274. PMID 21763169.
  5. ^ Goldin E, Slaugenhaupt SA, Smith J, Schiffmann R (2005) Mucolipidosis IV, GeneReviews at GeneTests: Medical Genetics Information Resource https://www.ncbi.nlm.nih.gov/books/NBK1214/
  6. ^ Altarescu, G.; Sun, M.; Moore, D. F.; Smith, J. A.; Wiggs, E. A.; Solomon, B. I.; Patronas, N. J.; Frei, K. P.; Gupta, S.; Kaneski, C. R.; Quarrell, O. W.; Slaugenhaupt, S. A.; Goldin, E.; Schiffmann, R. (2002). "The neurogenetics of mucolipidosis type IV". Neurology. 59 (3): 306–13. doi:10.1212/wnl.59.3.306. PMID 12182165. S2CID 21496744.
  7. ^ Goldin, E.; Caruso, R. C.; Benko, W.; Kaneski, C. R.; Stahl, S.; Schiffmann, R. (2008). "Isolated Ocular Disease is Associated with Decreased Mucolipin-1 Channel Conductance". Investigative Ophthalmology & Visual Science. 49 (7): 3134–42. doi:10.1167/iovs.07-1649. PMC 5267708. PMID 18326692.
  8. ^ Goldin, Ehud; Blanchette-Mackie, E Joan; Dwyer, Nancy K; Pentchev, Peter G; Brady, Roscoe O (1995). "Cultured Skin Fibroblasts Derived from Patients with Mucolipidosis 4 Are Auto-Fluorescent". Pediatric Research. 37 (6): 687–92. doi:10.1203/00006450-199506000-00003. PMID 7651750.
  9. ^ Chen, C. S.; Bach, G; Pagano, R. E. (1998). "Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease". Proceedings of the National Academy of Sciences of the United States of America. 95 (11): 6373–6378. Bibcode:1998PNAS...95.6373C. doi:10.1073/pnas.95.11.6373. PMC 27719. PMID 9600972.
  10. ^ Bach, Gideon; Webb, Michael B.T.; Bargal, Ruth; Zeigler, Marcia; Ekstein, Joseph (2005). "The frequency of mucolipidosis type IV in the Ashkenazi Jewish population and the identification of 3 novel MCOLN1 mutations". Human Mutation. 26 (6): 591. doi:10.1002/humu.9385. PMID 16287144.
  11. ^ Bargal, Ruth; Avidan, Nili; Olender, Tzvia; Ben Asher, Edna; Zeigler, Marcia; Raas-Rothschild, Annick; Frumkin, Ayala; Ben-Yoseph, Omer; Friedlender, Yechiel; Lancet, Doron; Bach, Gideon (2001). "Mucolipidosis type IV: NovelMCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population". Human Mutation. 17 (5): 397–402. doi:10.1002/humu.1115. PMID 11317355. S2CID 24741859.

External links

This page was last edited on 27 October 2023, at 15:03
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.